In addition to studying new companies, BSIMM 3 for the first time provides longitudinaldata on the security process at eleven of the thirty companies profiled in May 2010.
Second, Humedica gets to keep the de-identified but extremely valuable, comprehensive longitudinal patient data, package it, and sell it to interested third parties (e.g. payors and pharmas).